Literature DB >> 7254778

Gyrate atrophy of the choroid and retina. Biochemical considerations and experience with an arginine-restricted diet.

D Valle, M Walser, S Brusilow, M I Kaiser-Kupfer, K Takki.   

Abstract

Ornithine-delta-aminotransferase deficiency is the primary biochemical defect in gyrate atrophy of the choroid and retina and results in the characteristic accumulation of ornithine. An additional consequence of this inborn error is that arginine, the precursor of ornithine, becomes an essential amino acid. Therefore, to reduce the accumulated ornithine, we placed nine gyrate atrophy patients on an arginine-restricted diet. Plasma ornithine decreased by 50 to 85% within one month. Orally administered, alpha-aminoisobutyric acid facilitated the reduction in ornithine by augmenting renal losses. Over the long term, three patients have maintained near normal plasma ornithine concentrations from 4 to 32 months. Two patients have maintained less striking reductions in ornithine, and four have either been poorly controlled or have terminated the diet. Urinary losses of arginine and ornithine in gyrate atrophy patients with high or low plasma ornithine concentrations are less than 50% of the estimated arginine intake. This observation suggests that the bulk of ingested arginine is somehow metabolized despite the severe reduction in ornithine-delta-aminotransferase activity.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7254778     DOI: 10.1016/s0161-6420(81)35028-3

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  9 in total

1.  OAT mutations and clinical features in two Japanese brothers with gyrate atrophy of the choroid and retina.

Authors:  Satoshi Katagiri; Tamaki Gekka; Takaaki Hayashi; Hiroyuki Ida; Toya Ohashi; Yoshikatsu Eto; Hiroshi Tsuneoka
Journal:  Doc Ophthalmol       Date:  2014-01-16       Impact factor: 2.379

2.  Hepatic zonation of the catabolism of arginine and ornithine in the perfused rat liver.

Authors:  D O'sullivan; J T Brosnan; M E Brosnan
Journal:  Biochem J       Date:  1998-03-01       Impact factor: 3.857

3.  A mouse model of gyrate atrophy of the choroid and retina. Early retinal pigment epithelium damage and progressive retinal degeneration.

Authors:  T Wang; A H Milam; G Steel; D Valle
Journal:  J Clin Invest       Date:  1996-06-15       Impact factor: 14.808

4.  Gyrate atrophy: clinical and genetic findings in a female without arginine-restricted diet during her first 39 years of life and report of a new OAT gene mutation.

Authors:  Agnes B Renner; Andreas Walter; Britta S Fiebig; Herbert Jägle
Journal:  Doc Ophthalmol       Date:  2012-06-07       Impact factor: 2.379

5.  CRISPR correction of the Finnish ornithine delta-aminotransferase mutation restores metabolic homeostasis in iPSC from patients with gyrate atrophy.

Authors:  Rocio Maldonado; Sami Jalil; Timo Keskinen; Anni I Nieminen; Mervi E Hyvönen; Risto Lapatto; Kirmo Wartiovaara
Journal:  Mol Genet Metab Rep       Date:  2022-04-01

6.  Gyrate atrophy of choroid and retina with myopia, cataract and systemic proximal myopathy: A rare case report from rural India.

Authors:  Surekha Bangal; Akshay Bhandari; Priyanka Dhaytadak; Pratik Gogri
Journal:  Australas Med J       Date:  2012-12-31

7.  Clinical trials of vitamin B6 and proline supplementation for gyrate atrophy of the choroid and retina.

Authors:  S Hayasaka; T Saito; H Nakajima; O Takahashi; K Mizuno; K Tada
Journal:  Br J Ophthalmol       Date:  1985-04       Impact factor: 4.638

8.  Partial regression of foveoschisis following vitamin B6 supplementary therapy for gyrate atrophy in a Chinese girl.

Authors:  Wenxue Guan; Ge Wang; Feng Hu; Xiaoyan Peng
Journal:  BMC Ophthalmol       Date:  2021-02-18       Impact factor: 2.209

9.  Multimodal imaging of foveoschisis and macular pseudohole associated with gyrate atrophy: a family report.

Authors:  Imène Zhioua Braham; Imen Ammous; Rim Maalej; Majdi Boukari; Ilhem Mili Boussen; Khalil Errais; Raja Zhioua
Journal:  BMC Ophthalmol       Date:  2018-04-12       Impact factor: 2.209

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.